---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-045744"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2026-06-26T20:07:59+00:00"
generated_at: "2026-06-26T20:09:12.193075+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics stockholders approve increase in authorized common shares to 300M

## Summary
- Authorized common shares increased from 200M to 300M via Certificate of Amendment filed June 24, 2026.
- All seven director nominees elected with >63M votes for each; no dissident candidates.
- Ratification of CohnReznick LLP as independent auditor for FY2026 approved with 72.76M votes.
- 91.88M shares outstanding; 79.27% quorum at annual meeting.

## SEC filing metadata
- accession: 0001628280-26-045744
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2026-06-26T20:07:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/0001628280-26-045744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-045744
- JSON: https://secwatch.observer/filing/0001628280-26-045744.json
- Plain text: https://secwatch.observer/filing/0001628280-26-045744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.